Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

May 25, 2017

Phase 3 Clinical Trial to Test Opdivo in Mesothelioma Patients in United Kingdom

News

A Phase 3 British clinical trial will test whether the immune checkpoint inhibitor Opdivo (nivolumab) can help mesothelioma patients whose disease relapsed after platinum-based chemotherapy. The CONFIRM trial (NCT03063450), ... Read more

May 24, 2017May 24, 2017

Aduro, Merck to Begin Clinical Trial Assessing CRS-207, Keytruda Combo to Treat Worsening MPM

News

Aduro Biotech has expanded its collaboration with Merck to include an additional Phase 2 trial to test a combination of Aduro’s immunotherapy, CRS-207, with Keytruda (pembrolizumab) in patients with ... Read more

May 16, 2017May 16, 2017

TTFields, Which Alternates Forms of Electricity to Kill Mesothelioma Cells, Obtains an FDA Sign-off

News

The U.S. Food and Drug Administration has granted Humanitarian Use Device (HUD) status to Novocure‘s Tumor Treating Fields (TTFields) for treating pleural mesothelioma. The designation provides incentives to develop ... Read more

April 4, 2017

First Patient Dosed in Phase 1 Study of Genolimzumab for Mesothelioma, Other Solid Tumors

News

CBT Pharmaceuticals has enrolled the first participant in a Phase 1 trial assessing genolimzumab (CBT-501) as a treatment for recurrent or refractory solid tumors. The study is expected to include ... Read more

February 20, 2017

Family History of Melanoma Raises Risk for Mesothelioma, Other Cancers, Study Finds

News

Having first-degree relatives diagnosed with melanoma increases a person’s risk of pleural and peritoneal mesothelioma, a new study shows. Researchers believe that this is likely because the two cancers share common ... Read more

February 15, 2017

First Patient Begins Treatment in Trial of Combo Therapy for Advanced Solid Tumors

News

The first patient has begun treatment in a Phase 1 trial assessing a combination of Transgene’s Pexa-Vec, an oncolytic virus, and the immune checkpoint inhibitor Yervoy (ipilimumab) in advanced ... Read more

February 2, 2017February 2, 2017

Australian Mesothelioma Death Rates Higher Among Some Immigrant Groups

News

People who migrated to Australia from the United Kingdom, Ireland, Italy, and Germany had significantly higher mesothelioma death rates between 1981 and 2012 than those born in Australia, a ... Read more

January 9, 2017

Eagle Seeks FDA Approval of Ready-to-Dilute Alimta for Mesothelioma, NSCLC

News

Eagle Pharmaceuticals has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its novel ready-to-dilute pemetrexed (Alimta) formulation. The chemotherapy drug, which works by inhibiting ... Read more

December 19, 2016December 20, 2016

Mesothelioma Tumor Cells Can Generate Their Own Vasculature, Study Finds

News

Vasculogenic mimicry, a process in which tumor cells can form structures that resemble blood vessels and that can serve as blood conduits, is a common feature in malignant mesothelioma, ... Read more

December 15, 2016December 15, 2016

FDA Grants Nintedanib Orphan Drug Status to Treat Mesothelioma

News

The US Food and Drug Administration (FDA) has granted orphan-drug status to nintedanib as a treatment for the asbestos-related cancer mesothelioma. “Nintedanib, our triple angiokinase inhibitor, has shown promise ... Read more

Pin It on Pinterest